Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APRE Aprea Therapeutics, Inc.

Not Yet Opened 04-10 16:00:00 EDT

0.9168

+0.1828

+24.90%

盘后0.9000

-0.0168-1.83%

19:54 EDT

High0.9688	Low0.7341	Vol1.48M
Open0.7609	D1 Closing0.7340	Amplitude31.98%
Mkt Cap10.50M	Tradable Cap8.88M	Total Shares11.45M
T/O1.32M	T/O Rate15.30%	Tradable Shares9.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APRE","market":"US","secType":"STK","nameCN":"Aprea Therapeutics, Inc.","latestPrice":0.9168,"timestamp":1775851200000,"preClose":0.734,"halted":0,"volume":1481168,"hourTrading":{"tag":"盘后","latestPrice":0.9,"preClose":0.9168,"latestTime":"19:54 EDT","volume":33527,"amount":29581.5708,"timestamp":1775865262497,"change":-0.0168,"changeRate":-0.018325,"amplitude":0.065336},"delay":0,"changeRate":0.24904632152588552,"floatShares":9681100,"shares":11451118,"eps":-1.93,"marketStatus":"Not Yet Opened","change":0.1828,"latestTime":"04-10 16:00:00 EDT","open":0.7609,"high":0.9688,"low":0.7341,"amount":1320253.0938376,"amplitude":0.319755,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.93,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776067200000},"marketStatusCode":0,"adr":0,"listingDate":1570075200000,"exchange":"NASDAQ","adjPreClose":0.734,"preHourTrading":{"tag":"盘前","latestPrice":0.76,"preClose":0.734,"latestTime":"09:25 EDT","volume":3230,"amount":2434.9498734999997,"timestamp":1775827500220,"change":0.026,"changeRate":0.035422,"amplitude":0.095368},"postHourTrading":{"tag":"盘后","latestPrice":0.9,"preClose":0.9168,"latestTime":"19:54 EDT","volume":33527,"amount":29581.5708,"timestamp":1775865262497,"change":-0.0168,"changeRate":-0.018325,"amplitude":0.065336},"volumeRatio":10.017522328804157,"impliedVol":4.309,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/APRE/wiki","defaultTab":"wiki","newsList":[{"id":"2625956288","title":"Maxim Group Reaffirms Their Buy Rating on Aprea Therapeutics (APRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625956288","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625956288?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:55","pubTimestamp":1775570118,"startTime":"0","endTime":"0","summary":"In a report released today, Jason McCarthy from Maxim Group reiterated a Buy rating on Aprea Therapeutics, with a price target of $5.00. McCarthy c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-reaffirms-their-buy-rating-on-aprea-therapeutics-apre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-reaffirms-their-buy-rating-on-aprea-therapeutics-apre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624515660","title":"Aprea Therapeutics closes oversubscribed private placement raising $30 million gross proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515660","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515660?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:30","pubTimestamp":1775046624,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics closed an oversubscribed private placement with gross proceeds of about $30 million.Financing included pre-funded warrants covering about 37.2 million shares.Deal also included warrants covering about 37.2 million shares with an exercise price of $0.683 per share.Net proceeds will fund general corporate purposes, including R&D to advance APR-1051 clinical development.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDLbHgCT2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B64PRP62.GBP","BK4112","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4588","LU0314104364.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4139","SG9999014021.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","SG9999014039.USD","SG9999014013.SGD","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624515536","title":"Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515536","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515536?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:30","pubTimestamp":1775046600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUA8NY6RX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623300610","title":"Aprea Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $1.2 From $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2623300610","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623300610?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:10","pubTimestamp":1774951816,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nAZN4SO9G7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623345279","title":"BRIEF-Aprea Therapeutics Highlights Positive Emerging Clinical Activity For Wee1 Inhibitor, Apr-1051","url":"https://stock-news.laohu8.com/highlight/detail?id=2623345279","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623345279?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:51","pubTimestamp":1774878688,"startTime":"0","endTime":"0","summary":"BRIEF-Aprea Therapeutics Highlights Positive Emerging Clinical Activity For Wee1 Inhibitor, Apr-1051March 30 (Reuters) - Aprea Therapeutics Inc APRE.O:APREA THERAPEUTICS HIGHLIGHTS POSITIVE EMERGING C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA4CH9LK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623331756","title":"Aprea Therapeutics announces oversubscribed private placement raising about $30 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623331756","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623331756?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:07","pubTimestamp":1774872454,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics entered securities purchase agreement for oversubscribed private placement expected to raise about $30 million in gross proceeds.Offering includes pre-funded warrants for about 37 million shares priced at $0.81 each, less $0.001 per warrant.Investors also receive warrants for about 37 million shares with $0.68 exercise price, expiring Dec. 31, 2029.Proceeds earmarked for general corporate purposes, including research and development.Cash runway expected to extend into first quarter of 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL5WJ6GW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312078","title":"Aprea reports confirmed partial response for APR-1051 in Phase 1 ACESOT-1051 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312078","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312078?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:04","pubTimestamp":1774872265,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics reported a confirmed partial response in Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 in PPP2R1A-mutated endometrial cancer at 220 mg once daily.Response was previously disclosed at first imaging as 50% target-lesion reduction, then confirmed at second imaging with an additional 9.5% reduction.Trial has treated 24 patients across 10 mg to 220 mg once daily, with two partial responses in PPP2R1A-mutated endometrial cancer.Dose escalation continues, with move to 300 mg once daily planned in Q2 2026.Management guided to another trial update in Q2 2026, indicating results will be presented in the future.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL7XyPZc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2095319765.USD","BK4588","BK4112","LU2210149790.SGD","SG9999014005.SGD","NDAQ","IE00BKPKM429.USD","IE00BN0W2W23.USD","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623317559","title":"Aprea Therapeutics Inc - Expects Offering Proceeds to Extend Cash Runway Into Q1 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2623317559","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623317559?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:01","pubTimestamp":1774872060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUAB8NZF1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312249","title":"Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312249?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:01","pubTimestamp":1774872060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUAB8NZF1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623497312","title":"Aprea Therapeutics Highlights Positive Emerging Clinical Activity for Wee1 Inhibitor, Apr-1051, With a Confirmed Partial Response in the Ongoing Phase 1 Acesot-1051 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623497312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623497312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:00","pubTimestamp":1774872000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA4CH9LK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620460826","title":"Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620460826","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620460826?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:40","pubTimestamp":1773679205,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mineralys Therapeutics, Inc. (MLYS – Research Report...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mineralys-therapeutics-inc-mlys-and-aprea-therapeutics-apre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mineralys-therapeutics-inc-mlys-and-aprea-therapeutics-apre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4588","LU0029874061.USD","XBI","BK4585","BK4581","MLYS","BK4139","XLV","LABU","APRE","LU0128526141.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619946890","title":"Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2619946890","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619946890?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:00","pubTimestamp":1773662406,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA21VRNB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612269384","title":"Aprea Therapeutics files to sell 12.58M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2612269384","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612269384?lang=en_us&edition=fundamental","pubTime":"2026-02-20 19:11","pubTimestamp":1771585880,"startTime":"0","endTime":"0","summary":"06:08 EST Aprea Therapeutics (APRE) files to sell 12.58M shares of common stock for holders Published first on TheFly – the ultimate source for rea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-files-to-sell-12-58m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-files-to-sell-12-58m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","APRE","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612494344","title":"BRIEF-Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051","url":"https://stock-news.laohu8.com/highlight/detail?id=2612494344","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612494344?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:06","pubTimestamp":1771423609,"startTime":"0","endTime":"0","summary":"BRIEF-Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051Feb 18 (Reuters) - Aprea Therapeutics Inc APRE.O:APREA THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nTUA8ZCXM3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612463964","title":"Aprea Therapeutics announces additional clinical activity for APR-1051","url":"https://stock-news.laohu8.com/highlight/detail?id=2612463964","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612463964?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:17","pubTimestamp":1771420633,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics (APRE) announced additional preliminary data from the ongoing Phase 1 ACESOT-1051 trial evaluating its investigational WEE1 kina...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-announces-additional-clinical-activity-for-apr-1051-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-announces-additional-clinical-activity-for-apr-1051-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","APRE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612445164","title":"Aprea Therapeutics reports second partial response in APR-1051 ACESOT-1051 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2612445164","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612445164?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:02","pubTimestamp":1771419721,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc. reported additional preliminary data from its ongoing Phase 1 ACESOT-1051 trial evaluating the investigational WEE1 kinase inhibitor APR-1051 in advanced solid tumors. The company said a patient with advanced endometrial cancer treated at the 220 mg dose level achieved an unconfirmed partial response at the first on-treatment scan, with a 50% reduction in target lesions and a CA-125 decrease from 362 U/mL to 47 U/mL; the tumor harbored a PPP2R1A mutation and the patient experienced Grade 1 adverse events. Aprea also summarized that 22 patients have been treated across 10–220 mg, with two unconfirmed partial responses  and five cases of stable disease reported to date. The company said a further trial update is expected in the second quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL8bnrb7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","SG9999014021.USD","BK4585","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","APRE","LU2210149790.SGD","BK4139","SG9999014005.SGD","LU2210150020.SGD","NDAQ","LU2095319765.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612917445","title":"Aprea Therapeutics Inc - Update From Trial Is Expected in Q2 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612917445","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612917445?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:00","pubTimestamp":1771419608,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nTUA8ZCXM3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612445692","title":"Aprea Therapeutics Inc - Tumor Shrinkage of 50% and Significant CA-125 Biomarker Reduction Observed at 220 Mg Dose Level","url":"https://stock-news.laohu8.com/highlight/detail?id=2612445692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612445692?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:00","pubTimestamp":1771419608,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nTUA8ZCXM3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612445630","title":"Aprea Therapeutics Announces Additional Positive Clinical Activity for Wee1 Inhibitor, Apr-1051, Including Second Partial Response in Ongoing Acesot-1051 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2612445630","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612445630?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:00","pubTimestamp":1771419608,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nTUA8ZCXM3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610192475","title":"BRIEF-Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2610192475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610192475?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:02","pubTimestamp":1770904933,"startTime":"0","endTime":"0","summary":"BRIEF-Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer TherapeuticsFeb 12 (Reuters) - Aprea Therapeutics Inc APRE.O:APREA THERAPEUTICS STRENGTHENS GLOBAL PATE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA8RDH3K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aprea.com","stockEarnings":[{"period":"1week","weight":0.2815},{"period":"1month","weight":0.1649},{"period":"3month","weight":-0.03},{"period":"6month","weight":-0.3544},{"period":"1year","weight":-0.4085},{"period":"ytd","weight":0.0748}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.06034},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.033286},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.111168},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.095838},{"month":5,"riseRate":0,"avgChangeRate":-0.129229},{"month":6,"riseRate":0.333333,"avgChangeRate":0.023066},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.044399},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.005221},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.052829},{"month":10,"riseRate":0.333333,"avgChangeRate":0.013865},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.091344},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.053133}],"exchange":"NASDAQ","name":"Aprea Therapeutics, Inc.","nameEN":"Aprea Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aprea Therapeutics, Inc.(APRE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aprea Therapeutics, Inc.,APRE,Aprea Therapeutics, Inc.股票,Aprea Therapeutics, Inc.股票老虎,Aprea Therapeutics, Inc.股票老虎国际,Aprea Therapeutics, Inc.行情,Aprea Therapeutics, Inc.股票行情,Aprea Therapeutics, Inc.股价,Aprea Therapeutics, Inc.股市,Aprea Therapeutics, Inc.股票价格,Aprea Therapeutics, Inc.股票交易,Aprea Therapeutics, Inc.股票购买,Aprea Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aprea Therapeutics, Inc.(APRE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction